OAC
CBIO

OMERS Administration Corp’s Crescent Biopharma CBIO Stock Holding History

OMERS Administration Corp’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,800
Closed -$327K – 1011
2026
Q1 		$327K Buy
17,800
+6,200
+53% +$71.2K ﹤0.01% 843
2025
Q4 		$138K Buy
+11,600
New +$148K ﹤0.01% 949
2024
Q2 		– Sell
-306
Closed -$91.8K – 1115
2024
Q1 		$91.8K Buy
+306
New +$91.4K ﹤0.01% 329

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OMERS Administration Corp's CBIO Position: Q2 2026 in Review

OMERS Administration Corp sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 17,800 shares — an estimated $327K sold.

OMERS Administration Corp first reported a position in CBIO in Q1 2024 and held it in 3 quarters. The position peaked at $327K in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • OMERS Administration Corp reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 17,800 Crescent Biopharma shares in Q2 2026, an estimated $327K.
  • OMERS Administration Corp first reported a position in Crescent Biopharma in Q1 2024 and held it in 3 quarters.
  • OMERS Administration Corp's Crescent Biopharma position peaked at $327K in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.